Attaianese F, Guiducci S, Trapani S, Barbati F, Lodi L, Indolfi G
Pathogens. 2023; 12(9).
PMID: 37764926
PMC: 10536346.
DOI: 10.3390/pathogens12091118.
Arshad Dar H, Almajhdi F, Aziz S, Waheed Y
Vaccines (Basel). 2022; 10(9).
PMID: 36146460
PMC: 9502547.
DOI: 10.3390/vaccines10091381.
Cordova-Davalos L, Hernandez-Mercado A, Barron-Garcia C, Rojas-Martinez A, Jimenez M, Salinas E
Virus Genes. 2022; 58(6):501-514.
PMID: 36085536
PMC: 9462631.
DOI: 10.1007/s11262-022-01932-6.
Ftouh M, Kalboussi N, Abid N, Sfar S, Mignet N, Bahloul B
PPAR Res. 2021; 2021:6741290.
PMID: 34721558
PMC: 8550859.
DOI: 10.1155/2021/6741290.
Andrade C, Pacheco G, Galvez N, Soto J, Bueno S, Kalergis A
Viruses. 2020; 12(6).
PMID: 32545470
PMC: 7354512.
DOI: 10.3390/v12060637.
Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach.
Tahir Ul Qamar M, Shokat Z, Muneer I, Ashfaq U, Javed H, Anwar F
Vaccines (Basel). 2020; 8(2).
PMID: 32521680
PMC: 7350008.
DOI: 10.3390/vaccines8020288.
Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.
Jung H, Kim T, Lee H
Viruses. 2020; 12(1).
PMID: 31952261
PMC: 7020095.
DOI: 10.3390/v12010102.
Syncytia Formation in Oncolytic Virotherapy.
Burton C, Bartee E
Mol Ther Oncolytics. 2020; 15:131-139.
PMID: 31890866
PMC: 6931088.
DOI: 10.1016/j.omto.2019.09.006.
Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.
Carvajal J, Avellaneda A, Salazar-Ardiles C, Maya J, Kalergis A, Lay M
Front Immunol. 2019; 10:2152.
PMID: 31572372
PMC: 6753334.
DOI: 10.3389/fimmu.2019.02152.
Annexin A2 in Virus Infection.
Taylor J, Skeate J, Kast W
Front Microbiol. 2018; 9:2954.
PMID: 30568638
PMC: 6290281.
DOI: 10.3389/fmicb.2018.02954.
Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.
Mastrangelo P, Norris M, Duan W, Barrett E, Moraes T, Hegele R
Vaccines (Basel). 2017; 5(3).
PMID: 28925950
PMC: 5620558.
DOI: 10.3390/vaccines5030027.
Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection.
Van der Gucht W, Leemans A, De Schryver M, Heykers A, Caljon G, Maes L
Virol J. 2017; 14(1):157.
PMID: 28818113
PMC: 5561636.
DOI: 10.1186/s12985-017-0824-3.
New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.
Galvez N, Soto J, Kalergis A
Int J Mol Sci. 2017; 18(8).
PMID: 28800119
PMC: 5578143.
DOI: 10.3390/ijms18081753.
The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.
Bakre A, Harcourt J, Haynes L, Anderson L, Tripp R
Vaccines (Basel). 2017; 5(3).
PMID: 28671606
PMC: 5620547.
DOI: 10.3390/vaccines5030016.
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.
Rey-Jurado E, Kalergis A
Int J Mol Sci. 2017; 18(3).
PMID: 28273842
PMC: 5372572.
DOI: 10.3390/ijms18030556.
Human Respiratory Syncytial Virus: Infection and Pathology.
Bohmwald K, Espinoza J, Rey-Jurado E, Gomez R, Gonzalez P, Bueno S
Semin Respir Crit Care Med. 2016; 37(4):522-37.
PMID: 27486734
PMC: 7171722.
DOI: 10.1055/s-0036-1584799.
Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection.
Bellinghausen C, Gulraiz F, Heinzmann A, Dentener M, Savelkoul P, Wouters E
Respir Res. 2016; 17(1):68.
PMID: 27259950
PMC: 4891894.
DOI: 10.1186/s12931-016-0382-z.
Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.
Bakre A, Wu W, Hiscox J, Spann K, Teng M, Tripp R
J Gen Virol. 2015; 96(11):3179-3191.
PMID: 26253191
PMC: 4806578.
DOI: 10.1099/jgv.0.000261.
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner.
Jeong K, Piepenhagen P, Kishko M, DiNapoli J, Groppo R, Zhang L
PLoS One. 2015; 10(6):e0130517.
PMID: 26107373
PMC: 4479564.
DOI: 10.1371/journal.pone.0130517.
Challenges and opportunities in developing respiratory syncytial virus therapeutics.
Simoes E, DeVincenzo J, Boeckh M, Bont L, Crowe Jr J, Griffiths P
J Infect Dis. 2015; 211 Suppl 1:S1-S20.
PMID: 25713060
PMC: 4345819.
DOI: 10.1093/infdis/jiu828.